These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34914084)

  • 1. Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group.
    Dipasquale V; Martinelli M; Aloi M; Accomando S; Alvisi P; Arrigo S; Banzato C; Bramuzzo M; Cananzi M; Corpino M; Di Mari C; Di Nardo G; Dilillo A; Dodaro N; Felici E; Gatti S; Graziano F; Illiceto MT; Norsa L; Opramolla A; Pastore M; Pavanello PM; Romeo E; Scarallo L; Strisciuglio C; Zuin G; Romano C
    Paediatr Drugs; 2022 Jan; 24(1):57-62. PubMed ID: 34914084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars for Pediatric Patients With Inflammatory Bowel Disease: Pediatric Gastroenterology Clinical Practice Survey.
    Maltz RM; McClinchie MG; Boyle BM; McNicol M; Morris GA; Crawford EC; Moses J; Kim SC
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):616-621. PubMed ID: 36827968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
    Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
    Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians.
    Park SK; Moon W; Kim ES; Park SH; Park DI
    Korean J Gastroenterol; 2019 Dec; 74(6):333-340. PubMed ID: 31870139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease.
    Yossef L; Wright M; Benedict J; Morris GA; McNicol M; Boyle B; Dotson JL; Michel HK; Maltz RM
    J Pediatr Gastroenterol Nutr; 2022 Jul; 75(1):59-63. PubMed ID: 35442227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN.
    de Ridder L; Assa A; Bronsky J; Romano C; Russell RK; Afzal NA; Hauer AC; Knafelz D; Lionetti P; Strisciuglio C; Veres G; Winter H; Wolters VM; Sladek M; Vulto AG; Dias JA;
    J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):144-153. PubMed ID: 30169454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
    Tursi A; Mocci G; Cuomo A; Ferronato A; Elisei W; Picchio M; Maconi G; Scaldaferri F; Papa A; ; Allegretta L; Aragona G; Bianco MA; Colucci R; Della Valle N; Faggiani R; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Pica R; Pranzo G; Rodino' S; Sacco R; Sebkova L; Scarcelli A; Serio M; Napolitano D; Pugliese D; Schiavoni E; Turchini L; Armuzzi A; Zampaletta C
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):411-416. PubMed ID: 36535057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
    Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S
    United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
    Bokemeyer B; Dignaß A; Schreiber S
    Z Gastroenterol; 2017 Apr; 55(4):369-374. PubMed ID: 28056484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G; Caprioli F; Daperno M; Mocciaro F; Principi M; Viscido A; Fantini MC; Orlando A; Papi C; Annese V; Danese S; Vecchi M; Rizzello F; Armuzzi A;
    Dig Liver Dis; 2019 May; 51(5):632-639. PubMed ID: 30872085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients.
    Garcia KS; Facas BP; Machado MB; Teixeira FV; Avedano L; Lönnfors S; Hossne RS; Peyrin-Biroulet L; Queiroz NSF
    Therap Adv Gastroenterol; 2021; 14():17562848211013249. PubMed ID: 34046083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars.
    Demirkan FG; Sönmez HE; Lamot L; Akgün Ö; Sözeri B; Ayaz NA;
    BioDrugs; 2022 May; 36(3):421-430. PubMed ID: 35380389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G; Danese S
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
    Somers M; Bossuyt P; Ferrante M; Peeters H; Baert F
    J Crohns Colitis; 2020 Jun; 14(5):680-685. PubMed ID: 31875891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.